Q1 net income $91.2M on warrant gain; cash $466M; FDA grants COMP360 rolling NDA submission

COMPASS Pathways plc

2026-Q1 EPS reported -$0.30

FDA granted Compass NDA rolling submission for COMP360 in TRD based on positive Phase 3 data; CNPV awarded.
Net income $91.2M ($0.71 basic EPS) vs net loss $17.9M in Q1 2025; non-cash warrant gain of $130.9M.
Cash $466.0M at Mar 31 2026 (from $149.6M at Dec 31 2025); debt $50.5M (from $31.6M).
R&D expenses $26.5M (down from $30.9M); G&A $16.4M (down from $18.7M).
Final NDA submission on track for Q4 2026; 26-week COMP006 data expected early Q3 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

COMPASS Pathways plc reported for the three months ended March 31, 2026 results: net income $91.2 million, or $0.71 net income per share (basic) and $0.30 net loss per share (diluted), EPS $0.71 net income per share (basic) and $0.30 net loss per share (diluted). Guidance reaffirmed.

Period: for the three months ended March 31, 2026
Net income: $91.2 million, or $0.71 net income per share (basic) and $0.30 net loss per share (diluted)
EPS: $0.71 net income per share (basic) and $0.30 net loss per share (diluted)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Compass Pathways plc (the “Company”) issued a press release announcing the Company's financial results for the three months ended March 31, 2026.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

COMPASS Pathways plc filing history →

Source: SEC EDGAR

accession 0001816590-26-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.